MedTrace Logo

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

NCT07063875 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-07-14

No results posted yet for this study

Summary

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness.

This study aims to answer:

1. Can combining tebentafusp with IL-2 improve tumor response and overall survival?
2. What are the benefits and side effects of this combination therapy?

All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows:

Cycle1:

Day1-3 IL-2 Day4 Tebentafusp Day 10 IL-2 Day 11 Tebentafusp Day 17 IL-2 Day 18 Tebentafusp Day 24 IL-2 Day 25 Tebentafusp

Cycle 2 \& thereafter Day 1 IL-2 Day 2 Tebentafusp Day 8 IL-2 Day 9 Tebentafusp Day 15 IL-2 Day 16 Tebentafusp Day 22 IL-2 Day 23 Tebentafusp

Conditions

  • Uveal Melanoma
  • Metastatic Uveal Melanoma
  • Metastatic Uveal Melanoma in the Liver

Interventions

DRUG

Aldesleukin

IL-2 in combination with Tebentafusp

Sponsors & Collaborators

  • St Vincent's Hospital, Sydney

    lead OTHER

Principal Investigators

  • Anthony Joshua, FRACP · St Vincent's Hospital, Sydney

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07063875 on ClinicalTrials.gov